Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Massachusetts General Hospital
Western Sydney Local Health District
Institut Bergonié
Ascentage Pharma Group Inc.
Shenzhen BinDeBio Ltd.
University of Magdeburg
Wuhan University